Cryosupernatant plasma (also known as cryo-poor plasma, cryoprecipitate depleted [or reduced] plasma) is a product rendered from blood that is left to individual JWs to accept or decline purely as a personal choice.
For whatever reason(s), cryosupernatant plasma has never been mentioned in our publications addressing use of products rendered from blood. This despite cryoprecipitate plasma finding ready reference in the general search bar at jw.org.
Medical use of cryosupernatant plasma is said to have markedly improved medical outcomes for JWs who accept it, and particularly for those suffering from acquired thrombotic thrombocytopenic purpura (TTP). In this case the use of cryosupernatant is as a plasma exchange. The procedure uses an IV tube placed in a vein to remove blood from a TTP patient. The blood will traverse a cell separator to remove plasma from the blood. The non-plasma part of the blood is saved, and the donated cryosupernatant plasma is added to it (replacing the patient’s own blood plasma). The blood is then put back into the patient’s system through an IV line. This process can take a couple hours, and the plasma replacement therapy will continue daily for days or weeks until symptoms improve.
Because plasma makes up the majority of our circulating blood, as you can imagine, this procedure requires a lot of donated blood plasma.
Recently I have found this blood product cited for therapeutic use at jw.org, but not in the general search engine. To find this reference you have to navigate to the link for Medical Information for Clinicians page and use the search engine there. I’m unsure how long this reference has been there, but it is now.
So, though we don’t find this product on any of our diagrams, it is there, and it can save lives.
